TICKERNERD
Menu
ATNMATNMHealthcare · Biotechnology

ATNM Stock Forecast: Actinium Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.10
−1.79% on the day

The 4 Wall Street analysts covering Actinium Pharmaceuticals, Inc. hold a median 12-month price target of $3.5 — +218.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$34.5M
Ticker Nerd rank
69 / 100
Median analyst target
$3.50
Analysts covering
4
Total return, dividends reinvested
1W
+5.8%
1M
+22.2%
YTD
−19.1%
1Y
−35.7%
From 52W high
−38.5%
From 52W low
+46.9%
$0.75
$1.79
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATNM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Actinium Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
85
Quality
85
Revisions
81
Volatility
59
Issuance
45
Value
34
Accruals
31
Momentum
15

Growth (86): Sales and profits are climbing, and climbing faster than before.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATNM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATNM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26ATNMHigh $5.00Median $3.50Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $2.00Median $3.50High $5.00

The green dot is the last close — the median target sits +218.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Mar 2026Stephens & Co.ReiteratesOverweight—
24 June 2025HC Wainwright & Co.ReiteratesBuy—
12 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
20 Mar 2025HC Wainwright & Co.ReiteratesBuy—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Nov 2024Stephens & Co.ReiteratesOverweight—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024HC Wainwright & Co.MaintainsBuy—
6 Aug 2024Maxim GroupMaintainsBuy—
26 July 2024HC Wainwright & Co.ReiteratesBuy—
17 June 2024HC Wainwright & Co.ReiteratesBuy—
21 May 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024Stephens & Co.InitiatesOverweight—
2 May 2024HC Wainwright & Co.ReiteratesBuy—
30 Apr 2024Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATNM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ATNM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Actinium Pharmaceuticals, Inc. (ATNM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.1×

Cheaper than 68% of US stocks

Price / sales
1.0×

Cheaper than 70% of US stocks

Price / book
1.1×

Cheaper than 69% of US stocks

EV / EBITDA
−0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
78.8%

Higher than 99% of US stocks

Net margin
32.2%

Higher than 91% of US stocks

Returns & dividend
Return on equity
45.9%

Higher than 92% of US stocks

Return on assets
11.6%

Higher than 94% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ATNM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATNMActinium Pharmaceuticals, Inc.$34.5M
69
BCTXBriaCell Therapeutics Corp.$35.1M
7
NNVCNanoViricides, Inc.$33.8M
58
LITSLite Strategy, Inc.$35.3M
28
QNCXQuince Therapeutics, Inc.$33.2M
25
IGCIGC Pharma, Inc.$31.8M
6
ESLAEstrella Immunopharma, Inc.$30.9M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Actinium Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATNM news & analysis

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

PRNewsWire · 14 Aug 2026positive

Actinium Pharmaceuticals announced intellectual property and manufacturing advances for its Actimab-A program, including recently acquired patents and expanded manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 into 2027. The company also provided an update on the status of its NYSE American listing.

Why it matters — ATNM watchers would care because the program is nearing key clinical milestones, and the patent, manufacturing, and listing updates could affect the company's near-term positioning and visibility.

FAQ

Frequently asked questions about ATNM stock

What is the ATNM stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Actinium Pharmaceuticals, Inc. have a median 12-month price target of $3.5, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATNM stock a buy right now?

Of the 4 analysts covering Actinium Pharmaceuticals, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Actinium Pharmaceuticals, Inc. 69 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATNM?

As at 22 Aug 2026, Actinium Pharmaceuticals, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will ATNM stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +218.2% from the last close, and Ticker Nerd's factor model ranks Actinium Pharmaceuticals, Inc. 69 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATNM stock forecast for 2030?

No analyst covering Actinium Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has ATNM stock performed over the past year?

Actinium Pharmaceuticals, Inc. returned -35.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Actinium Pharmaceuticals, Inc. do?

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer.

What is the latest news on ATNM?

The most recent item we track (PRNewsWire, 14 Aug 2026): "Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update". Actinium Pharmaceuticals announced intellectual property and manufacturing advances for its Actimab-A program, including recently acquired patents and expanded manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 into 2027. The company also provided an update on the status of its NYSE American listing.

Company

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer. The company's primary aim is to harness the power of radioisotopes in conjunction with proprietary tumor-targeting agents to improve outcomes for patients with difficult-to-treat cancers. Actinium's flagship platform, Antibody Radiation-Conjugates (ARCs), is designed to deliver potent radiation directly to cancer cells, minimizing exposure to healthy tissues and enhancing the potency of therapeutic regimens. Operating in the highly competitive pharmaceutical sector, Actinium's research is concentrated on hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes. The company plays a significant role in the niche of targeted radiotherapy, an area gaining traction for its promise in personalized medicine. Actinium Pharmaceuticals leverages collaborations with renowned research institutions to advance its pipeline and bring novel treatments to patients. Positioned at the intersection of oncology and radiopharmaceuticals, Actinium aims to set new standards in cancer treatment while addressing unmet medical needs."

CEO Mr. Sandesh C. Seth M.B.A., M.S. · 27 employees · United States · https://www.actiniumpharma.com